invest1 distinct publisher
An mRNA vaccine cleared Phase 3 on Keytruda, and the read-through lands on Alteogen
Moderna and MSD's V940 hit both endpoints in adjuvant melanoma. The commercial consequence sits with Keytruda SC, whose conversion rate reached 10.6% in July.
Publishers:en.sedaily.com
Reality
- Evidence52
- Adoption44
- Hype gap+24
- Incentives72
- Confidence45